$1.74
+0.14 (+8.75%)
Open$1.66
Previous Close$1.60
Day High$1.77
Day Low$1.66
52W High$26.04
52W Low$14.90
Volume—
Avg Volume582.2K
Market Cap42.28M
P/E Ratio36.03
EPS$0.67
SectorBiotechnology
Analyst Ratings
Strong Sell
6 analysts
Price Target
+1,319.5% upside
Current
$1.74
$1.74
Target
$24.70
$24.70
$17.28
$24.70 avg
$43.03
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 10.04M | 9.21M | 8.21M |
| Net Income | 1.01M | 1.19M | 806.0K |
| Profit Margin | 10.1% | 12.9% | 9.8% |
| EBITDA | 1.65M | 1.73M | 1.63M |
| Free Cash Flow | 1.05M | 900.3K | 756.9K |
| Rev Growth | +21.1% | -0.3% | +20.3% |
| Debt/Equity | 1.00 | 0.87 | 0.86 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $223.43 | +2.01% | 165.4 | 394.89B |
| AMGN | Amgen Inc | $384.32 | +4.49% | 26.8 | 206.95B |
| GILD | Gilead Sciences Inc | $152.50 | +2.10% | 23.3 | 189.20B |
| VRTX | Vertex Pharmaceuticals Inc | $477.92 | +4.17% | 33.7 | 123.82B |
| REGN | Regeneron Pharmaceuticals | $785.51 | +2.46% | 18.4 | 83.03B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.16 | -0.93% | 995.2 | 43.35B |